Idazoxan hydrochloride is an α2-adrenoceptor antagonist and imidazoline receptor (IRs) antagonist that competitively antagonizes the central hypotensive effects of imidazoline-like drugs (IMs); it also improves Parkinson's disease, L-DOPA-induced dyskinesia, and motor symptoms in experimental Parkinsonism; additionally, it potently reverses haloperidol-induced catalepsy in rats with an ED50 of 0.25 mg/kg.